Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25364996 | 1.00 | GPR119 (0.42) | GPR119KCNJ1CYP2D6PTGS2CA12 | |
| SCHEMBL25367392 | 0.96 | GPR119 (0.42) | GPR119KCNJ1CYP2D6PTGS2CA12 | |
| SCHEMBL30541576 | 0.96 | GPR119 (0.42) | GPR119KCNJ1CYP2D6PTGS2CA12 | |
| SCHEMBL30541615 | 0.89 | GPR119 (0.38) | GPR119KCNJ1PTGS2CA12CA1 | |
| SCHEMBL25364364 | 0.89 | GPR119 (0.38) | GPR119KCNJ1PTGS2CA12CA1 | |
| SCHEMBL25364132 | 0.86 | GPR119 (0.44) | GPR119CYP2D6 | |
| SCHEMBL30541639 | 0.85 | GPR119 (0.39) | GPR119PTGS2CA12CA1CA2 | |
| SCHEMBL25366291 | 0.85 | GPR119 (0.39) | GPR119PTGS2CA12CA1CA2 | |
| SCHEMBL25365718 | 0.85 | GPR119 (0.43) | GPR119 | |
| SCHEMBL25366102 | 0.84 | GPR119 (0.37) | GPR119PTGS2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479407-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | claimed |
| EP-4479407-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |